Sales Enablement

Week ending August 9, 2026

1. What’s coming up in conversations this week

• Ozempic vs. Wegovy and weight loss: People are asking whether they are “the same medicine or just different brands,” and why an ad emphasizes weight loss when Ozempic’s labeled use is for type 2 diabetes. AI answers consistently distinguish shared semaglutide from different products, doses, and indications.
• Dosing and missed doses: Questions include “What is the recommended starting dose… and how often should I inject it?” and “If I miss a dose… should I skip it or take it later?” Dosing was one of the most frequent themes (76 tagged responses).
• Safety in practical patient situations: Expect questions about insulin or sulfonylureas, kidney disease, pancreatitis symptoms, thyroid-tumor warnings, pregnancy/breastfeeding, and contraindications.
• Source and substitution concerns: Patients are asking about compounded semaglutide, “generic Ozempic,” biosimilars, and pharmacy offers of another semaglutide brand.
• Perceived effectiveness: Prescribers may hear that Ozempic is “stronger” than Trulicity or that Mounjaro produces greater appetite reduction or weight loss.

2. Competitive talking points

• Wegovy — 46 mentions: AI frames Ozempic and Wegovy as sharing semaglutide but differing in approved use, dosing, and product labeling. Be ready to separate product/indication questions from generalized weight-loss discussion.
• Mounjaro — 26 mentions: AI emphasizes Ozempic as a GLP-1 receptor agonist versus Mounjaro as a dual GIP/GLP-1 agonist, with claims that tirzepatide may deliver “greater” or “more potent” appetite and weight effects. Treat “stronger,” “more potent,” and “greater weight loss” as circulating AI language—not verified messaging to repeat.
• Trulicity — 25 mentions: AI frequently says Ozempic is perceived as “more effective,” “stronger,” or “superior,” especially for weight loss and A1C. If raised, anchor the discussion to the specific outcome, population, study design, and each product’s approved labeling rather than repeating a blanket superiority claim.
• Rybelsus — 11 mentions: The common question is whether shared semaglutide means identical safety messaging; AI generally says core warnings overlap, while route and labeling emphasis differ.

3. Questions and objections to be ready for

• “Can I use Ozempic for weight loss without diabetes?” High patient relevance; AI answers distinguish Ozempic’s diabetes label from weight-management labeling for another product.
• “What should I do if I miss a dose?” Answers conflict materially—some cite 48 hours, others five days. Reps should direct clinicians to the current prescribing information rather than improvise.
• “Can someone with kidney disease use Ozempic?” AI usually says no routine renal dose adjustment, but monitoring matters if GI effects cause dehydration; answers vary on whether hypoglycemia or contraindication language is included.
• “What claims are actually supported versus Trulicity or Mounjaro?” Responses inconsistently include warnings and contraindications, making a concise, label-grounded answer important.

4. What’s changed since last week

This is a high-volume rebound: responses rose from 70 to 140, while inconsistency flags increased from 34 to 39. Fresh growth is strongest in dosing (+44), overclaim language (+24), and competitor mentions—Wegovy +23, Mounjaro +15, and Trulicity +14. Compounded/generic questions also doubled or nearly doubled versus the prior week.

5. Recommended actions

1. Add a call-prep box on Ozempic vs. Wegovy and weight-loss indications.
2. Refresh missed-dose and dosing materials against the current prescribing information.
3. Prepare a neutral response framework for “stronger/superior” Trulicity or Mounjaro claims.
4. Add a practical compounded/generic/source distinction talking point.
5. Remind reps to escalate patient-specific safety, pregnancy, pancreatitis, kidney, and interaction questions to the prescriber/approved medical resources.